Grail Raises $390M in Series D

Grail has successfully raised $390M in a Series D at a $6.3B valuation led by ARCH Venture Partners, Johnson & Johnson.

Company Overview

Grail is a Biotech company headquartered in Menlo Park, CA, founded in 2016 with 500+ employees.

Multi-cancer early detection blood test

Fundraising Details

• Amount Raised: $390M
• Round Type: Series D
• Valuation: $6.3B
• Date: 2020-05-27
• Investors: ARCH Venture Partners, Johnson & Johnson

About Grail

Multi-cancer early detection blood test The company is positioned in the Biotech sector, serving a growing market with innovative solutions.

Key Information

• Headquarters: Menlo Park, CA
• Founded: 2016
• Team Size: 500+
• Industry: Biotech

What This Means

This funding round demonstrates strong investor confidence in Grail's vision and execution. The capital will likely be used to:

• Scale Operations: Expand the team and operational capacity
• Product Development: Enhance existing products and develop new features
• Market Expansion: Enter new markets and strengthen presence in existing ones
• Technology Investment: Invest in infrastructure and technology capabilities

Industry Context

The Biotech sector continues to attract significant investment as companies innovate to meet evolving market demands. Grail's successful fundraising reflects the strong fundamentals and growth potential in this space.

Valuation Milestone

Reaching a $6.3B valuation marks an important milestone for Grail, positioning the company among notable players in the Biotech industry.

Looking Ahead

With this new capital, Grail is well-positioned to execute on its growth strategy and continue building innovative solutions in the Biotech space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.

This fundraising news was reported on 2020-05-27. For more information about Grail, visit their headquarters at Menlo Park, CA.